# Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

> **NCT04908813** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 150 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** HLX22
- **DRUG:** Placebo
- **DRUG:** Trastuzumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04908813
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-29
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908813, "Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04908813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*